This Article Full Text Full Text (PDF) All Versions of this Article: 36/12/e165    most recent 01.STR.0000190893.74268.fdv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abou-Chebl, A. Articles by Yadav, J. S. Search for Related Content PubMed PubMed Citation Articles by Abou-Chebl, A. Articles by Yadav, J. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TAXOL Related Collections Angiography Primary and Secondary Stroke Prevention Angioplasty and Stenting

(Stroke. 2005;36:e165.)
© 2005 American Heart Association, Inc.

Short Communication

Drug-Eluting Stents for the Treatment of Intracranial Atherosclerosis

Initial Experience and Midterm Angiographic Follow-up

From the Departments of Neurology (A.A.-C., Q.B., J.S.Y.) and Cardiovascular Medicine (J.S.Y.), The Cleveland Clinic Foundation, Cleveland, Ohio.

Correspondence to S. Yadav, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail yadavj{at}ccf.org

Background and Purpose— Intracranial stenting is associated with a 32% rate of restenosis. Drug-eluting stents (DES) have revolutionized the treatment of coronary artery disease and have greatly reduced the risk of in-stent stenosis. We present our experience with the feasibility and safety of using DES for patients with symptomatic intracranial atherosclerosis.

Methods— All of the patients had >70% stenoses and had failed maximal medical therapy. They were pretreated with aspirin, clopidogrel, and intraprocedural heparin. All of the lesions were predilated, and balloons and stents were slightly undersized. Clopidogrel and aspirin were continued for 1 year, and patients had clinical follow-up and vascular imaging at 30 days, 6 months, and 1 year.

Results— Eight patients with intracranial internal carotid artery (3), middle cerebral (2), basilar (2), and vertebral artery (1) stenoses were successfully treated with 4 Cypher (Cordis Corp) and 4 Taxus (Boston Scientific Inc) stents. The mean stenosis severity was reduced from 84.4%±10.2% to 2.5%±4.6%. One patient had an intraprocedural retinal embolism, but there were no other complications. Over a mean follow-up of 11.1±4.9 months (range, 2 to 17.3 months), patients have had repeat angiography (5) or transcranial Doppler with or without CT angiography (3). None of the patients have had clinical or significant angiographic restenosis or required target vessel revascularization.

Conclusions— Elective intracranial stenting with DES appears to be feasible and safe, but additional clinical experience is required to assess its efficacy.

Key Words: angiography • intracranial arterial diseases • ischemia • stents

This article has been cited by other articles:

				T J Wolfe, B F Fitzsimmons, S I Hussain, J R Lynch, and O O Zaidat Long term clinical and angiographic outcomes with the Wingspan stent for treatment of symptomatic 50-99% intracranial atherosclerosis: single center experience in 51 cases JNIS, July 3, 2009; (2009) jnis.2009.000331v1. [Abstract] [Full Text] [PDF]

				D Fiorella, T N Turan, C P Derdeyn, and M I Chimowitz Current status of the management of symptomatic intracranial atherosclerotic disease: the rationale for a randomized trial of medical therapy and intracranial stenting JNIS, July 3, 2009; (2009) jnis.2009.000125v1. [Abstract] [Full Text] [PDF]

				K. Groschel, S. Schnaudigel, S. M. Pilgram, K. Wasser, and A. Kastrup A Systematic Review on Outcome After Stenting for Intracranial Atherosclerosis Stroke, May 1, 2009; 40(5): e340 - e347. [Abstract] [Full Text] [PDF]

				H. C. Schumacher, P. M. Meyers, R. T. Higashida, C. P. Derdeyn, S. D. Lavine, G. M. Nesbit, D. Sacks, P. Rasmussen, and L. R. Wechsler Reporting Standards for Angioplasty and Stent-Assisted Angioplasty for Intracranial Atherosclerosis Stroke, May 1, 2009; 40(5): e348 - e365. [Abstract] [Full Text] [PDF]

				M. Mazighi, J. S. Yadav, and A. Abou-Chebl Durability of Endovascular Therapy for Symptomatic Intracranial Atherosclerosis Stroke, June 1, 2008; 39(6): 1766 - 1769. [Abstract] [Full Text] [PDF]

				O. O. Zaidat, R. Klucznik, M. J. Alexander, J. Chaloupka, H. Lutsep, S. Barnwell, M. Mawad, B. Lane, M. J. Lynn, M. Chimowitz, et al. The NIH registry on use of the Wingspan stent for symptomatic70-99% intracranial arterial stenosis Neurology, April 22, 2008; 70(17): 1518 - 1524. [Abstract] [Full Text] [PDF]

				E. Mahmud, J. J. Cavendish, and A. Salami Current Treatment of Peripheral Arterial Disease: Role of Percutaneous Interventional Therapies J. Am. Coll. Cardiol., August 7, 2007; 50(6): 473 - 490. [Abstract] [Full Text] [PDF]

				D. Fiorella and H. H. Woo Emerging Endovascular Therapies for Symptomatic Intracranial Atherosclerotic Disease Stroke, August 1, 2007; 38(8): 2391 - 2396. [Full Text] [PDF]

				R. Gupta, F. Al-Ali, A. J. Thomas, M. B. Horowitz, T. Barrow, N. A. Vora, K. Uchino, M. D. Hammer, L. R. Wechsler, and T. G. Jovin Safety, Feasibility, and Short-Term Follow-Up of Drug-Eluting Stent Placement in the Intracranial and Extracranial Circulation Stroke, October 1, 2006; 37(10): 2562 - 2566. [Abstract] [Full Text] [PDF]